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ABSTRACT 
Objective: The objective of the present work was to formulate and evaluate a stable, odour free garlic powder loaded floating matrix tablet for the 
treatment of peptic ulcers.  
Methods: A gastro-retentive floating matrix tablet (FMT) formulation of garlic powder (GP) was prepared using various concentrations of 
hydroxypropyl methylcellulose K4M (HPMC K4 M) and effervescent system (sodium bicarbonate and citric acid in 1:1 % w/w) to achieve desirable 
floating time (FT), floating lag time (FLT) and drug release. Wet granulation method was selected using ethanol as a binder for preparation of tablet. 
32
Results: It was observed that FMT with optimum quantities of HPMC K4M and the effervescent system showed 97 % of drug release in 12 h with FT 
up to 10 h and minimum FLT of 3 min. There was no significant change in FLT, FT and drug content during the stability study of FMT. 
 full factorial designs were used for selection of suitable polymer concentration and effervescent system. Nonenteric film coating was applied to 
mask GP odour. 
Conclusion: A stable, sustained release FMT of GP tablets using HPMC K4M and an effervescent system was successfully prepared. This formulation 
can overcome problems of taste and odour masking, gastric irritation, and loss of active constituents present in garlic. 
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Peptic ulcers are chronic, most often solitary, lesions that occur in 
any portion of the gastrointestinal tract exposed to the aggressive 
action of acid-peptic juices. As much as 80% of ulcers are associated 
with Helicobacter pylori, a spiral-shaped bacterium that lives in the 
acidic environment of the stomach [1]. 
Garlic was procured from the local market and the whole sample of 
garlic plant was authenticated (Auth08-022) by Agarkar Research 
Institute, Pune, Maharashtra, India. Hydroxypropyl methylcellulose 
K4M (HMPC K4M), cross caramelose sodium, aerosil PH 200, talc, 
magnesium stearate were received from Himedia Labs, Mumbai, 
India. Avicel PH 102 was donated by Dow Chemical Company, 
Mumbai. All other chemicals used in the study were of an analytical 
grade. 
Preparation of garlic powder  
Garlic cloves were peeled and kept in a hot air oven, temperature 
maintained between 50 °C to 55 °C. Dried garlic cloves were 
powdered with suitable grinder. Moisture loss of garlic cloves was 
determined by percent weight loss per day till a constant weight was 
achieved.  
Analytical method 
The HPTLC method was developed for analysis of the GP in the 
tablet formulation. The 500 mg GP was weighed accurately and 
dissolved in 25 ml water containing ethanol as a co-solvent with 
constant stirring for 15 min. Then the solution was filtered with the 
help of Whatmman filter paper and dilutions were made to obtain 4-
14 µg/ml solutions. 12 µl of each dilution was spotted with the help 
of HPTLC syringe on HPTLC plate. The area obtained for each ml 
solution was then presented by CAMAGE software.  
Formulation development 
A 3
Treatment usually involves a 
combination of antibiotics, acid suppressors, and stomach 
protectors i.e.14-tablet/day for a week or more. Although antibiotic 
therapy has a success rate of 80%-90%, problems including 
undesirable side effects, high cost and poor patient compliances are 
associated with significant levels of treatment failure. Development 
of microbial resistance and contraindications is also observed in 
some patients [2]. 
Peptic ulcers can be treated successfully by herbal medicines 
without any side-effects. The aim of the study was to formulate a 
stable gastro-retentive dosage form containing garlic for local action 
in the stomach to treat peptic ulcers caused by H. pylori. 
Garlic clove, garlic aqueous extracts, garlic powder, garlic oil, and 
allicin have been proved to be effective against H. pylori [3]. The 
powder form of garlic is the most stable starting material for the 
formulation, as the antibacterial principle i.e. allicin is formed from 
alliin present in garlic powder (GP), in situ and its biotransformation 
products are also effective against H. pylori. Allicin was found to be 
more stable in 20% alcohol than in water [4]. However, a patient 
cannot take garlic powder or raw garlic cloves as such because of 
gastric irritation and strong odour associated with the high dose 
needed for antibacterial action. The present work highlights the 
novel herbal formulation aimed specifically for the treatment of 
Helicobacter pylori infection to heal gastric ulcers. This formulation 
is very significant for the emerging nutraceutical market as garlic is 
one of the topmost selling nutraceuticals internationally.  
MATERIALS AND METHODS 
2
Three levels (Low, medium and high) for each factor were selected 
as shown in table 1. All the other formulation ingredients like aerosil 
PH 200, croscarmellose sodium, talc, magnesium stearate were kept 
invariant throughout the study for all 9 formulation batches of 
floating matrix tablet (FMT). 
 full Factorial design (Design Expert version 7.1) was 
constructed where the concentration of sodium bicarbonate and 
citric acid (A) and amount of polymer (B) were independent 
variables and floating time (FT) and floating lag time (FLT) were 
dependent variables.  
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-1 0 1 
 A [% w/w of effervescent system(sodium bicarbonate: citric acid 1:1 w/w)] 6 9 12 
B (% w/w of HPMC K4M) 7 14 21 
 
All the ingredients (except magnesium stearate, talc) were weighed 
accurately and mixed along with 50 % of weighed aerosil PH 200 by 
geometrical proportion. Then ethanol was added in a small fraction 
to obtain wet mass. The granules were prepared by wet granulation 
method. Then the accurately weighed magnesium stearate, talc 
along with the remaining amount of aerosil was mixed and added in 
a granular mixture. The final blend compressed, using concave 
punches having length size 21.00 mm and 10.5 mm in width. 5% 
w/w non-enteric coating of HPMC was applied on FMT. The final 
weight of tablet after coating for all formulations was 900 mg [9]. 
  
Table 2: Composition of FMT formulations 
S. No. Ingredients  Amount (% w/w) 
F F1 F2 F3 F4 F5 F6 F7 F8 9 
1 Garlic Powder 60 60 60 60 60 60 60 60 60 
2 HPMC K4M 7 21 7 7 14 14 14 21 21 
3 Sodium bicarbonate and citric acid (1:1 w/w) 6 6 12 9 9 12 6 9 12 
4 Croscarmellose sodium 1 1 1 1 1 1 1 1 1 
5 Avicel 102 20.5 6.5 14.5 17.5 10.5 7.5 13.5 3.5 0.5 
6 Aerosil PH200 3 3 3 3 3 3 3 3 3 
7 Magnesium stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
8 Talc 2 2 2 2 2 2 2 2 2 
9 Ethanol q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. 
 
Physical characterization  
All the batches were evaluated for weight variation, hardness, 
friability, thickness as per USP XXV monograph. The weight 
variation was determined by taking 20 tablets using electronic 
balance. Tablet hardness was determined for 10 tablets using a 
Monsanto tablet hardness tester. Friability was determined by 
testing 20 tablets in a Roche friability tester for 4 min at 25 rpm. 
Buoyancy lag time and duration of buoyancy (FLT and FT)  
The time interval between the introduction of a tablet into the 
dissolution medium and its buoyancy to the top of dissolution 
medium was taken as FLT and FT was observed visually [10].  
Assay 
The content of active constituent(s) in garlic powder was 
determined by HPTLC method. For the preparation of standard 
solution, 500 mg GP was dissolved in distilled water (25 ml) and 
ethanol as a co-solvent with constant stirring for 15 min and 
filtered by Whatmman filter paper (Sample A). For the 
preparation of test solution, garlic tablet was crushed and 
dissolved in 25 ml distilled water containing ethanol as a co-
solvent with constant stirring for 15 min and filtered by 
Whatmman filter paper (Sample B). Then the equivalent strength 
solutions of A and B samples (µl) were spotted by HPTLC syringe on 
HPTLC plate. Then areas of both were measured to determine % 
drug content.  
In vitro drug release 
Drug release was calculated based on HPTLC fingerprint method. 
900 ml 0.1 N HCl was selected as dissolution media at 50 rpm, 
36.5°C–37.5°C using USP XXIII (Type1). One Gelusil tablet was 
added in dissolution medium to adjust the pH for maintaining the 
stability of GP. The 5 ml sampling was taken and replaced with 
equivalent amount till 12 h with fresh dissolution media.  
Evaluation of tablet coating film 
The tablet coating film was prepared by spraying the coating 
solution on a plain glass surface at the flow rate of 3 ml/min for 
15 min as required for tablet coating. This film was evaluated for 
thickness, bursting strength and water vapour permeability.  
The thickness of coated FMT was measured using Vernier Calipers, 
Water vapour permeability was determined at 25 °C using 
desiccators containing calcium chloride for 72 h.  
Stability testing 
The accelerated stability studies were performed on formulations F8 and 
F9 as per the protocol. FT, FLT, drug content, tablet thickness, weight 
variation, and hardness were tested at periodic time intervals.  
RESULT AND DISCUSSION  
Authentification of garlic sample 
The whole sample of the garlic plant was identified as Allium sativum 
Linn (Family-Liliaceae)  
Physical characterization of FMT  
The formulated floating matrix tablets met the pharmacopoeia 
requirement of hardness, drug content, friability, weight variation 
and thickness (table 3).  
 
 
Fig. 1: Floating behaviour of FMT F
 
9 
Formulation and development 
The purpose of using 32full factorial design was to conduct a 
comprehensive study of the effect of process parameters like 
concentration of sodium bicarbonate and citric acid (A) and amount 
of HMPC K4M (B) and their interactions using a suitable statistical 
tool (Design expert software version7.1) by applying one-way 
ANNOVA at 0.05 levels. A mathematical modelling was carried out. 
Polynomial equation was obtained depending on significant 
influences among 2 factors on their experimental design. 
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The fitted equations relating the response FT and FLT to the 
transformed factor are shown in the equation I, equation II respectively.  
. . . I 
. . II 
The values of correlation coefficient indicate a good fit. 
The three-dimensional response surface plot was generated by 
software. The response surface plot is very useful for the 
determination of main and interaction effects of the independent 
variables. The response surfaces plots for each response parameter 
are presented for further interpretation of the results (fig. 2, fig. 3). 
Formulations F8 and F9 were considered as optimized formulations 
on the basis of FT and FLT. 
The data demonstrated that both factors A and B affect FT and FLT. 
As the concentration of B increased from 7 % to 21% FT is increased 
up to 10 h. FLT in increased up to 4 min as sodium bicarbonate and 
citric acid concentration increases for 6 to 12 % w/w. Desirable FLT 
i.e. 3 min and FT i.e. 10 h are achieved by increasing concentration of 
HPMC K4M and maintaining the optimum concentration of sodium 
bicarbonate and citric acid. 
The buoyant delivery systems utilize matrices by swellable 
polymers such as Methocel (HPMC) or polysaccharides e. g. chitosan 
and effervescent components e. g., sodium bicarbonate and citric 
acid or tartaric acid or matrices containing chambers of liquids that 
gasify at body temperature.  
The matrices are fabricated so that upon arrival in the stomach, 
carbon dioxide is liberated by the acidity of the gastric contents and 
is entrapped in jellified hydrocolloid. This produces an upward 
motion of dosage form and maintains its buoyancy. Among the 
gastro-retentive dosage forms, effervescent matrix floating tablet is 
formulated as it overcomes the problem of acidic degradation of GP 
and it is able to sustain the release of drug in the stomach with 
gastric retention. 
  















* FT  
(min 
*(h)  
1 F 5.2±0.2 1 3.5±0.2 0.64±0.1 96.45± 0.5±0.8 7±0.2 5±0.5 
2 F 5.3±0.1 2 3.5±0.2 0.61±0.1 95.12± 0.6±0.5 5±0.5 5.7±0.3 
3 F 5.3±0.2 3 3.4±0.1 0.65±0.1 98.25± 0.7±0.9 6±0.3 4.5±0.2 
4 F 5.2±0.4 4 3.5±0.1 0.66±0.2 98.65± 0.8±0.8 5.5±0.2 5±0.4 
5 F 5.3±0.2 5 3.2±0.3 0.7±0.2 96.80± 0.7±0.7 3.5±0.5 7±0.2 
6 F 5.3±0.2 6 3.5±0.2 0.65±0.3 95.32± 0.7±0.5 3.8±0.3 8±0.5 
7 F 5.2±0.1 7 3.4±0.4 0.71±0.3 95.27± 0.8±0.5 3.6±0.4 9±0.5 
8 F 5.2±0.2 8 3.5±0.2 0.65±0.2 97.35± 0.8±0.5 3.0±0.5 10±0.2 
9 F 5.3±0.3 9 3.5±0.2 0.62±0.2 98.22± 0.8±0.3 3.5±0.5 10±0.2 
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Fig. 3: Response surface plot showing an effect of independent variables (A and B) on response FLT (Y) 
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In vitro drug release study  
Sustained drug release was observed for F8,  F9 formulations in 0.1 N 
HCl (fig. 4). The assay of tablets revealed that the total GP content of 
the F9 tablet was found to be 94.48% and for F8
  
 found to release 
97% of active constituents in 12 h. Slow drug release is because of 
swelling of HMPC K4M that delays drug release from the tablet 
matrix. As a result of the rheology of hydrated product, the swollen 
particles coalesce. This results in a continuous viscoelastic matrix 
that fills the interstices, maintaining the integrity of the tablet, and 
retarding further penetration of the dissolution medium tablets 






























Fig. 4: In vitro drug release of FMT formulations F8 and F9 
 
Gastro retentive dosage forms are developed to deliver the drug in 
gastric region. The main intention of this dosage form is to retain drug 
in a gastric environment for a longer period of time with control 
release of drug to obtain the desirable local action or drug absorption. 
Drug release mechanism 
A decrease in release kinetics of the drug was observed by 
increasing the polymer concentration.  
(mean±SD of three replicate experiments) 
The in vitro drug release profile was applied in different 
mathematical models and was interpreted in the form of graphical 
presentation and evaluated by the correlation coefficient (R2) 
represented in table 4. The highest degree of correlation coefficient 
determines the suitable mathematical model that follows drug 
release kinetics [
It was concluded that the optimized formulations F
16]. 
8 and F9
Evaluation of tablet coating film 
 followed 
zero order release 
The thickness of the non-enteric film coated FMT was found to be 
5.2 mm with hazy appearance having 30% water vapour 
permeability. 
Stability studies  
The accelerated stability studies at 40 °C/75% RH were performed 
on formulation F8 as per the protocol. Drug content, FT, FLT, 
hardness and thickness were tested at periodic time intervals. As 
shown in table 5, F8
  
 formulation was found to be stable for the 
tested period under the accelerated storage conditions 
Table 4: Results of different models in terms of R2, slope and intercept for F8 and F9. 
 FModel name 8  F  9  
R2  Slope  Intercept  R2  Slope  Intercept  
0.993 Zero order model  8.330 2.557 0.997 7.895 1.541 
First order model  0.8322  -0.4206  2.1673  0.9212  -0.3808  2.1079  
Higuchi model  0.991  47.823  0.000  0.9916  48.976  0.0000  
Korsmeyer-Peppas model  -4.156  3.1562  0.000  -4.09  3.1875  0.0000  
Hixson-Crowell model  0.9586  0.8122  0.0213  0.9897  0.7911  0.0416  
Kinetics as it showed the highest linearity ((R2 = 0.993 and R2 = 0.997) respectively. Also, the model Korsmeyer-Peppas power law equation states 
the type of diffusion, which was evaluated by value, n which is higher than 0.89 which implies that the drug release from the system follows Super 
case II transport 
 
[16].  
Table 5: Physicochemical analysis of formulation F8
Time interval 
 during stability study 
Thickness* Hardness (mm) * (kg/cm2 FLT) * FT (min) * Weight variation (h) * Drug content% * % 
Initial  5.3±0.2 3.5±0.5 3.5±0.5 10±0.5 0.62±0.1 85.09±0.8 
1 Mo 5.3±0.3 3.5±0.3 3.5±0.8 10±1.5 0.62±0.2 85.09±0.2 
2 Mo 5.3±0.5 3.5±0.5 3.7±0.4 10±0.5 0.62±0.1 84.90±0.5 
3 Mo 5.3±0.4 3.5±0.5 3.7±0.5 10±0.5 0.62±0.3 84.78±0.3 
*Values given in the table are the mean±SD of three replicate experiments (n=3), t-test was performed to verify if any statistically significant 
changes are noted in tested stability samples against the initial sample. However, there was no significant change in all the parameters during the 
stability study against initial values. 
Pawar et al. 




From the study, it was concluded that a stable, sustained release, 
FMT formulation of GP was successfully prepared. This formulation 
can overcome problems of taste and odour masking, gastric 
irritation and loss of active constituents present in garlic. A twice-a-
day dosing of the GP tablet (preceded by an antacid) can be a viable 
substitute to the standard triple therapy for the treatment of peptic 
ulcers. This formulation may be used in clinical trials to confirm the 
therapeutic properties of garlic, especially antibacterial activity 
against H. pylori as it is the most reliable dosage form to reap all 
benefits of garlic. 
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